HIV medicine · 2026
Stability of the HIV cascade of care throughout the COVID-19 pandemic in Europe: Results from the multinational EuroSIDA cohort study (2016-2022).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fursa Olga, Bannister Wendy, Guaraldi Giovanni, Kowalska Justyna, Miro Jose M, Zangerle Robert, Jilich David, Viard Jean-Paul, Kusejko Katharina, Nowak Piotr, Domingo Pere, Mackintosh Claire, Castagna Antonella, Benfield Thomas, Szetela Bartosz, Bogner Johannes, Boffito Marta, Peters Lars, EuroSIDA study group
Аннотация
BACKGROUND: Prior to the COVID-19 pandemic, antiretroviral therapy (ART) coverage and viral suppression were improving across Europe; however, the impact of the pandemic on HIV care remains uncertain.
METHODS: In-person visits, ART coverage and viral suppression among those on ART were described in the EuroSIDA cohort for each calendar year from 2016 to 2022 and compared across five European regions. Multivariable logistic regression was used to assess factors associated with having an in-person visit and with viral suppression.
RESULTS: Among 6740 participants, 71.9% were men, 34.9% were MSM, and the median age was 50 years (IQR: 42-56) at baseline (2016). The proportion of in-person visits dropped from 75.0% in 2019 to 67.8% in 2020, increased to 74.5% in 2021 and was 72.3% in 2022. We observed a consistent increase in ART uptake over the years and a slight increase in missing HIV-RNA data in 2020. The odds of attending clinic in person were lower in 2020 compared with 2016 (aOR: 0.81, 95% CI 0.75-0.87) but not in 2021 or 2022, while viral suppression increased over calendar time (p < 0.0001). Compared to Central-Western Europe, the other regions had lower odds of in-person visits (p < 0.0001, most prominently for Southern Europe, aOR: 0.18) and viral suppression (p < 0.0001, most prominently for Eastern Europe, aOR: 0.07).
CONCLUSIONS: Our study confirmed the resilience of HIV care across Europe during the COVID-19 pandemic, whereas the regional and country differences in clinic attendance and viral suppression highlighted the need to address persisting gaps in HIV care on a national level.
METHODS: In-person visits, ART coverage and viral suppression among those on ART were described in the EuroSIDA cohort for each calendar year from 2016 to 2022 and compared across five European regions. Multivariable logistic regression was used to assess factors associated with having an in-person visit and with viral suppression.
RESULTS: Among 6740 participants, 71.9% were men, 34.9% were MSM, and the median age was 50 years (IQR: 42-56) at baseline (2016). The proportion of in-person visits dropped from 75.0% in 2019 to 67.8% in 2020, increased to 74.5% in 2021 and was 72.3% in 2022. We observed a consistent increase in ART uptake over the years and a slight increase in missing HIV-RNA data in 2020. The odds of attending clinic in person were lower in 2020 compared with 2016 (aOR: 0.81, 95% CI 0.75-0.87) but not in 2021 or 2022, while viral suppression increased over calendar time (p < 0.0001). Compared to Central-Western Europe, the other regions had lower odds of in-person visits (p < 0.0001, most prominently for Southern Europe, aOR: 0.18) and viral suppression (p < 0.0001, most prominently for Eastern Europe, aOR: 0.07).
CONCLUSIONS: Our study confirmed the resilience of HIV care across Europe during the COVID-19 pandemic, whereas the regional and country differences in clinic attendance and viral suppression highlighted the need to address persisting gaps in HIV care on a national level.